Answers are grounded in this paper and cite their sources.
Observational analysis finds progression of pulmonary arterial systolic pressure predicts poor prognosis in multiple myeloma, highlighting the need for regular check-ups.
Background and objectives Multiple myeloma (MM) is the second most common hematological malignancy characterized by an uncontrolled neoplastic proliferation of plasma cells within bone marrow and extramedullary sites. Although cardiovascular pathology is not uncommon, pulmonary hypertension (PH) is an infrequently encountered complication of MM. We investigated the impacts of progression pulmonary arterial systolic pressure (PASP) measured by echocardiography after chemotherapy on prognosis in patients with MM. Methods A total of 107 MM patients who had both baseline and post-chemotherapy echocardiography were divided into 2 groups; Progression PASP group (n=52, 55.1±9.8 years, 30 males) vs no progression PASP group (n=55, 56.6±8.4 years, 24 males). PH was defined as the peak velocity of tricuspid regurgitation > 2.8m/s, and Progression PASP was defined as the development of de novo PH or the increase of PASP > 10 mmHg at follow up echocardiography as compared to baseline echocardiography. No change of PASP on follow up echocardiography was considered as no progression PASP group in this study. Clinical, laboratory, and echocardiographic findings were compared between the groups. Results PH was detected in 62 patients (57.9%) at baseline echocardiography. De novo PH was detected in 17 cases (15.8%), and aggravated PASP was diagnosed in 35 cases (37.5%). There were no significant differences in baseline characteristics between the groups except that atrial fibrillation was more common in progression PASP group (19.2 vs 3.6%, p=0.025). There were no significant differences in chemo-therapeutic regimen between the groups except for the frequent application of peripheral blood stem cell transplantation in no progression PASP group. During 2.4 ± 1.2 years of FU, 48 patients were died (30 death in progression PASP vs 18 death in no progression PASP group, p=0.016). In Kaplan Meier survival analysis, death or cardiac death free survival was significantly lower in progression PASP group than in no progression PASP group (figure 1). Conclusion PH was common in patients with MM. Progression PASP after chemotherapy was significantly associated with poor prognosis in MM. Therefore, careful monitoring and regular checkup of PASP by echocardiography should be performed in patients with MM for the identification of high risk group.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: